Drugs / YK012
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07234474 | Oct 2026 → Nov 2027 expected | membranous glomerulonephritis | Excyte Biopharma Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07512947 | May 2026 → Mar 2028 expected | systemic lupus erythematosus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06982729 | Mar 2025 → Dec 2026 expected | idiopathic membranous glomerulonephritis | Excyte Biopharma Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06565689 | May 2023 → Dec 2028 expected | B-cell non-Hodgkin lymphoma | Excyte Biopharma Ltd | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07010835 | Aug 2025 → Jun 2027 expected | systemic lupus erythematosus | Excyte Biopharma Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06580301 | Sep 2024 → Dec 2026 expected | B-cell acute lymphoblastic leukemia | Excyte Biopharma Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YK012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07010835 ↗ |
| Action | Deplete | “leading to T cell-mediated cytotoxicity of malignant B cells” NCT06565689 ↗ |
| Route | Intravenous | “administered with YK012 by intravenous infusion” NCT06565689 ↗ |
| Target | CD19 | “targeting CD19 on B cells” NCT06982729 ↗ |